Seres Therapeutics
MCRB
63 hedge funds and large institutions have $43.1M invested in Seres Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 11 closing their positions.
238% more call options, than puts
Call options by funds: $132K | Put options by funds: $39K
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.08% less ownership
Funds ownership: 1.85% → 1.76% (-0.08%)
9% less funds holding
Funds holding: 69 → 63 (-6)
18% less capital invested
Capital invested by funds: $52.5M → $43.1M (-$9.41M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$872K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$305K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$171K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$160K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.46M |
| 2 |
Millennium Management
New York
|
-$1.39M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$58.2K |
| 4 |
Jane Street
New York
|
-$48.8K |
| 5 |
CF
Cantor Fitzgerald
New York
|
-$45.6K |
MCRB Hedge Fund Activity: Q1 2025 in Review
63 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2025, worth a combined $43.1M — down 18% from $52.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MCRB and 5 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 16 added.
The largest buyer was UBS Group, adding an estimated $872K. The largest seller was Morgan Stanley, cutting an estimated $1.46M.
- 63 institutional investors held Seres Therapeutics (MCRB) as of Q1 2025, down from 69 in Q4 2024.
- Funds reported $43.1M of Seres Therapeutics stock for Q1 2025, down 18% quarter-over-quarter.
- 5 funds opened new Seres Therapeutics positions in Q1 2025 and 11 closed out, a net change of -6 holders.
- The largest Seres Therapeutics buyer in Q1 2025 was UBS Group, an estimated $872K added.
- The largest Seres Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.46M sold.
Based on aggregated 13F filings for Q1 2025.